Inclusion Criteria:

All cohorts:

- Female subjects more than 18 years of age

- Performance status must be ECOG 0-2.

- Adequate organ function

- Measurable disease by RECIST version 1.1 or CA125 progression according to the GCIG
definition (Vergote et al).

- Written informed consent

Ovarian, fallopian tube or peritoneal carcinoma cohort:

- Histologically confirmed diagnosis of invasive epithelial ovarian,fallopian tube, or
peritoneal carcinoma (serous, mucinous, endometrioid,clear cell, or carcinosarcomas
are eligible).

- Patients should have received at least 1 earlier platin treatment but should be
platin refractory (progression within 28 days after the last dose of platin) or
platin resistant (progression within 6 months after last dose of platin therapy).

- Earlier weekly or dose-dense regimens with paclitaxel and carboplatin are not
allowed. Consolidation after the last platin dose with non-platinum containing
chemotherapy or molecular targeted drugs is allowed

Endometrial carcinoma cohort

- Histologically confirmed diagnosis of endometrial carcinoma
(endometrioid,adenoacanthoma, adenosquamous, serous, clear cell carcinoma or
carcinosarcomas are eligible).

- Recurrent or advanced endometrial carcinoma can be included.

- Earlier platin therapy is allowed. But earlier weekly or dose-dense regimens with
paclitaxel and carboplatin are not allowed.

Cervical carcinoma cohort

- Histologically confirmed diagnosis of cervical carcinoma (adenocarcinoma or squamous
carcinomas are eligible).

- Recurrent or advanced endometrial carcinoma can be included.

- Earlier platin (including concomitant with radiotherapy) therapy is allowed. But
earlier weekly or dose-dense regimens with paclitaxel and carboplatin are not
allowed.

Exclusion Criteria:

- Other histologies than those mentioned above such as non-epithelial ovarian
carcinomas, neuro-endocrine tumors, sarcomas, metastases from other primary tumors,
...

- Earlier weekly or dose-dense paclitaxel and carboplatin regimen.

- Any unstable or serious condition e.g. uncontrolled infection requiring systemic
therapy.

- Prior other malignancies treated primarily or for recurrence within 3 years prior to
inclusion in this study, except for completely resected non- melanomatous skin
carcinoma or successfully treated in situ carcinoma of the skin or cervix of the
uterus.

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with subject's safety, provision of informed consent, or
compliance to study procedures

- Metastatic disease to the brain or leptomeninges.

- Treatment with any of the following anti-cancer therapies:

- radiation therapy, surgery or tumor embolization within 14 days prior to the first
dose of study chemotherapy.

- chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal
therapy within 14 days or five half-lives of a drug (whichever is longer) prior to
the first dose of study drug

- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs similar
or related to Paclitaxel, Carboplatin or G-CSF.